The DOI matches its Crossref record, with a small difference in title or year; 30 of the 31 references it cites were found in a registry or an index; 52 of the 68 sources its claims cite were checked for support.
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Open accessAbstract
BACKGROUND: Neoadjuvant use of immune checkpoint inhibitors (ICIs) before liver resection results in pathological tumour regression in patients with hepatocellular carcinoma. We aimed to describe the characteristics of pathological responses after preoperative ICI therapy for hepatocellular carcinoma and to evaluate the association between the depth of tumour regression and relapse-free survival. METHODS: In this cross-trial, patient-level analysis, we performed a pooled analysis of data from patients with hepatocellular carcinoma receiving ICI therapy before liver resection as part of a global collaborative consortium (NeoHCC) of five phase 1 and 2 clinical trials and standardised observational protocols conducted in 12 tertiary referral centres across the USA, UK, and Taiwan. Eligible patients were adults (aged ≥18 years) diagnosed with hepatocellular carcinoma by tissue core biopsy before treatment initiation, a Liver Imaging Reporting and Data System score of 5 on imaging, or both, with an Eastern Cooperative Oncology Group performance status score of 0-1, and no extrahepatic spread or previous ICI treatment. Pathological response was measured as the percentage of non-viable tumour in the resected surgical specimen, with major pathological response corresponding to at least 70% tumour regression and pathological complete response corresponding to 100% tumour regression. We correlated pathological response with radiological overall response using RECIST criteria (version 1.1) and relapse-free survival, and evaluated the threshold of tumour regression that could be optimally associated with relapse-free survival. FINDINGS: At data cutoff on Jan 31, 2024, 111 patients were included in the study, of whom data on pathological response were available for 104 (94%) patients. Patients received treatment from Oct 5, 2017, to Nov 15, 2023, mostly ICI combinations (76 [69%]), for a median of 1·4 months (IQR 0·7-2·9). 87 (78%) patients were men and 24 (22%) were women. Most patients had underlying viral chronic liver disease (73 [66%]) and Barcelona Clinic Liver Cancer stage A hepatocellular carcinoma (61 [55%]), without portal vein thrombosis (87 [78%]). We observed major pathological response in 33 (32%) patients and pathological complete response in 19 (18%) patients. Radiological overall response was associated with major pathological response, with 23 (74%) of 31 patients with radiological response showing major pathological response compared with ten (14%) of 73 patients without radiological response (p<0·0001). However, ten (30%) of 33 major pathological responses were not predicted by radiological response. After a median follow-up of 27·2 months (95% CI 22·3-32·1), median relapse-free survival for the whole cohort was 43·6 months (95% CI 28·3-not evaluable). Relapse-free survival was significantly longer in patients with major pathological response than in those who did not have a major pathological response (not reached [95% CI not evaluable-not evaluable] vs 28·3 months [12·8-43·8]; hazard ratio 0·26 [0·10-0·66]; p=0·0024) and in patients with pathological complete response than in those who did not have a pathological complete response (NR [95% CI not evaluable-not evaluable] vs 32·8 months [15·0-50·5]; 0·19 [0·05-0·78]; p=0·010). Unbiased recursive partitioning of the cohort for the risk of relapse, death, or both identified a threshold of 90% as the optimal cutoff of pathological tumour regression to predict improved relapse-free survival. INTERPRETATION: The extent of tumour regression following neoadjuvant ICI therapy could identify patients with improved relapse-free survival following liver resection. The threshold of at least 90% tumour regression should be validated for its surrogate role for relapse-free survival in phase 3 randomised controlled trials. FUNDING: None.
Overview
CoChat Summary
TL;DR
In a cross-trial, patient-level pooled analysis of 111 patients with hepatocellular carcinoma receiving neoadjuvant immune checkpoint inhibitors before liver resection, major pathological response occurred in 33 (32%) and pathological complete response in 19 (18%). Depth of pathological response was associated with improved relapse-free survival, and an optimal 90% tumour-regression threshold was identified for predicting relapse-free survival.
Key findings
- Among 104 pathologically evaluable patients, major pathological response (≥70% non-viable tumour) occurred in 33 (32%) and pathological complete response (100%) in 19 (18%); the distribution was bimodal, with 85 (82%) of 104 samples showing either <25% or >75% response.
- After median follow-up of 27·2 months (95% CI 22·3–32·1), median relapse-free survival for the whole cohort was 43·6 months (95% CI 28·3–not evaluable). Major pathological response was associated with longer relapse-free survival (not reached vs 28·3 months; HR 0·26 [95% CI 0·10–0·66]; p=0·0024), as was pathological complete response (not reached vs 32·8 months; HR 0·19 [0·05–0·78]; p=0·010).
- Radiological overall response was associated with major pathological response: 23 (74%) of 31 patients with radiological response vs 10 (14%) of 73 without (p<0·0001), but 10 (30%) of 33 major pathological responses were not predicted by radiological response.
- Unbiased recursive partitioning identified 90% as the optimal pathological tumour-regression cutoff for predicting relapse-free survival; Youden’s index on the ROC curve for 24-month relapse-free survival estimated an optimal threshold of 92·5% (sensitivity 93·8%, specificity 29·0%), while the 70% threshold had sensitivity 84·4% and specificity 39·1%.
Methods
- Design: cross-trial, patient-level pooled analysis within the NeoHCC consortium, including five phase 1 and 2 clinical trials and standardised observational protocols at 12 tertiary referral centres in the USA, UK, and Taiwan; data cutoff was Jan 31, 2024, with 111 patients treated from Oct 5, 2017, to Nov 15, 2023.
- Participants: adults aged ≥18 years with hepatocellular carcinoma diagnosed by tissue core biopsy before treatment initiation or LI-RADS score 5 on imaging, ECOG performance status 0–1, and no extrahepatic spread or previous immune checkpoint inhibitor treatment. Pathological response was measured as percentage of non-viable tumour in the resected specimen; major pathological response was ≥70% regression and pathological complete response was 100% regression.
- Analysis: Kaplan–Meier estimates and Cox regression models for relapse-free survival and time to relapse; radiological response assessed by RECIST version 1.1 (modified RECIST in a subset); recursive partitioning and ROC/Youden’s index to identify the optimal response threshold; frailty models and centre-level cluster correction were applied.
Limitations
- Paper-stated limitations include heterogeneous tumour presentations (from resectable BCLC stage A to upfront unresectable tumours), varied ICI-based treatments and durations, different timing of response assessment across protocols, sample size insufficient to definitively confirm surrogacy, inability to perform internal random cross-validation of recursive partitioning models, absence of central histological review, no pooled translational biomarker analysis, and no prospectively enrolled control group.
- Evident from the text: the analysis pools early-phase and observational data without a randomised comparator, and overall survival data were not mature, with only 13 (12%) deaths recorded, limiting assessment of longer-term survival outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2: Pathological responses of surgical samples from patients after neoadjuvant immunotherapy and association with radiological responses (A) Pathological responses assessed in the surgical samples by percentage of tumour regression (n=104). (B) The correlation between change in tumour size based on radiological assessment (RECIST criteria [version 1.1]) and pathological response of each surgical specimen. (C) Waterfall plot for the depth of pathological response, with different bar colours according to radiological response as per RECIST criteria (version 1.1); the dashed line represents major pathological response (70% tumour regression). RECIST=Response Evaluation Criteria in Solid Tumours.](https://figures.cochat.ai/paper-figures/4b587c4963ec45c7828d93ed8d7bf498/pathological-response-following-neoadjuvant-immune-checkpoint-inhibitors-in-figure-2.jpg)

Verification
Claims the paper makes
15 Valid · 3 Not valid · 9 Not checked · 86 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical data have shown that, compared with surveillance, inhibitors of the PD-1 pathway with or without bevacizumab can lead to an improvement in relapse-free survival after liver resection.5,6”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Introduction
What the sources say
- Not checked — no full text of the sourcecites [5] Wang, 2024, Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial, Nat Med source
- Partly supportedcites [6] Qin, 2023, Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial, Lancet sourceExperimental — accuracy not yet measured
The Results report improved recurrence-free survival with atezolizumab (a PD-L1 inhibitor) plus bevacizumab versus active surveillance, and Table 1 shows that most participants underwent resection. The trial also included patients treated by ablation and did not test a PD-1-pathway inhibitor without bevacizumab; the Discussion says the relative benefits of single-agent and combination treatment remain to be established. Page numbers were not provided in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, none of these studies were individually powered to robustly investigate predictive factors of efficacy from neoadjuvant ICI therapy, particularly with regards to long-term survival outcomes, including relapse-free survival.”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Discussion
What the sources say
- Partly supportedcites [7] Marron, 2022, Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial, Lancet Gastroenterol Hepatol sourceExperimental — accuracy not yet measured
The Methods (Statistical analysis) show that this trial’s sample size was calculated to test a response rate, not predictors of efficacy or long-term survival. The Discussion says larger controlled trials are needed to establish a response threshold that correlates with survival. The paper does not establish that every study referred to by the citing authors was underpowered for predictive-factor analyses, particularly relapse-free survival. (LLM, conf=0.83)
- Supportedcites [8] Kaseb, 2022, Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial, Lancet Gastroenterol Hepatol source
The Discussion states that this small study was not powered to formally compare clinical outcomes, pathological response, and immune correlates. Methods identifies safety as the primary objective and biomarker correlates as exploratory; Methods and Results describe recurrence-free survival as a post-hoc analysis. Together, these passages support the claim as it applies to this cited study, rather than establishing the power of every study mentioned by the citing authors. (LLM, conf=0.88)
- Supportedcites [9] Ho, 2021, Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity, Nat Cancer source
For this study, the Methods describe safety and feasibility as the primary endpoint, with response correlates and disease-free survival as exploratory endpoints. The Results say the small number of patients precluded formal statistical comparisons, and the Discussion says the small sample and short follow-up precluded precise interpretation of how responses affected disease-free survival. The paper supports the claim about its own study, not a conclusion about every study in the citing sentence. (LLM, conf=0.88)
- Partly supportedcites [10] Xia, 2022, Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial, J Immunother Cancer sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) says this trial had a small sample and about one year of follow-up, and that a larger sample is needed to substantiate its proposed predictor of relapse. Patient follow-up (page not supplied) reports an RFS comparison that was not statistically significant, possibly because of the small sample. These passages support the limitation for this trial, but do not establish that none of the other studies was adequately powered. (LLM, conf=0.84)
- Partly supportedcites [11] Pinato, 2021, PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma, BMC Cancer sourceExperimental — accuracy not yet measured
The Planned sample size and study period section says PRIME-HCC was safety-oriented, with efficacy assessed preliminarily before a future adequately powered trial. The Outcome measures and endpoints section treats survival and response biomarkers as exploratory, but specifies progression-free and overall survival, not relapse-free survival. This paper also cannot establish whether every other study referred to in the citing sentence was underpowered. (LLM, conf=0.85)
- Partly supportedcites [12] Su, 2021, P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma, Ann Oncol sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) reports 29 enrolled patients and says long-term follow-up is needed to clarify whether treatment reduces recurrence after surgery. That supports the concern about immature long-term outcomes, but it does not state that the study was underpowered to investigate predictive factors or report relapse-free survival; it reports an exploratory gene-expression association with progression-free survival instead. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [25] D'Alessio, 2023, Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma, Proc Am Soc Clin Oncol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The use of ICIs as a neoadjuvant treatment before liver resection for patients with hepatocellular carcinoma has been explored in several single-centre phase 1 and 2 clinical trials.”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Discussion
What the sources say
- Partly supportedcites [7] Marron, 2022, Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial, Lancet Gastroenterol Hepatol sourceExperimental — accuracy not yet measured
The Methods describe a phase 2 trial of neoadjuvant cemiplimab followed by resection in patients with hepatocellular carcinoma. The Discussion identifies this trial and one other as the first reported trials in this setting; it does not establish the claim of several single-centre phase 1 and 2 trials. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [8] Kaseb, 2022, Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial, Lancet Gastroenterol Hepatol sourceExperimental — accuracy not yet measured
The Methods (Study design and participants; page unavailable) describe a single-centre phase 2 trial of nivolumab with or without ipilimumab before liver resection in patients with hepatocellular carcinoma. That supports the claim's general point, but this paper documents one phase 2 trial, not several phase 1 and 2 trials. (LLM, conf=0.86)
- Partly supportedcites [9] Ho, 2021, Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity, Nat Cancer sourceExperimental — accuracy not yet measured
The Methods (Study design; page unavailable) describe a single-institution phase 1b trial of neoadjuvant cabozantinib and nivolumab before possible liver resection. The Discussion mentions another neoadjuvant immunotherapy study, but this paper does not establish the claim that several single-centre phase 1 and 2 trials explored the approach. (LLM, conf=0.84)
- Partly supportedcites [10] Xia, 2022, Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial, J Immunother Cancer sourceExperimental — accuracy not yet measured
The Study flow section describes this phase II trial giving neoadjuvant camrelizumab before hepatectomy in patients with resectable HCC. The Introduction says only a few studies had examined neoadjuvant immunotherapy in HCC, but the copy does not substantiate the more specific claim that several single-centre phase 1 and 2 trials had done so. (LLM, conf=0.82)
- Partly supportedcites [11] Pinato, 2021, PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma, BMC Cancer sourceExperimental — accuracy not yet measured
The Neoadjuvant immunotherapy section (page unavailable) describes PRIME-HCC as a phase Ib study of checkpoint inhibitors before liver resection in HCC. But it calls the study multi-centre and presents its design and rationale; it does not substantiate the claim that several single-centre phase 1 and 2 trials had explored this use. (LLM, conf=0.86)
- Partly supportedcites [12] Su, 2021, P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma, Ann Oncol sourceExperimental — accuracy not yet measured
The Abstract (page not provided) describes a clinical study of nivolumab plus ipilimumab as neoadjuvant treatment for potentially resectable hepatocellular carcinoma; fifteen participants underwent surgery. It does not state the study’s phase or whether it was single-centre, and this one study does not establish that several such trials were conducted. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [25] D'Alessio, 2023, Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma, Proc Am Soc Clin Oncol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In other cancer types, the endpoint to define response to neoadjuvant therapy has been pathological complete response (100%)13,15 or near-pathological complete response (>90%).29”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Discussion
What the sources say
- Partly supportedcites [13] Patel, 2023, Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion mentions a complete or near-complete pathological response as a criterion being investigated in neoadjuvant melanoma trials. It does not define near-complete response as >90% or establish that threshold as an endpoint in other cancer types. The Results define complete pathological response as no viable tumor, but the citation attached to this source follows the near-complete-response claim. (LLM, conf=0.78)
- Supportedcites [15] Conforti, 2021, Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis, BMJ source
The Methods section defines pathological complete response by the absence of specified disease in the breast, with or without the lymph nodes, and uses it as the response endpoint in neoadjuvant breast-cancer trials. The citing sentence attaches separate citation 29 to near-pathological complete response (>90%); that portion is not attributed to this source. (LLM, conf=0.90)
- Partly supportedcites [29] Hellmann, 2014, Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint, Lancet Oncol sourceExperimental — accuracy not yet measured
Section 2 (page unavailable) proposes major pathological response as ≤10% residual tumor tissue—approximately >90% response—as an endpoint after neoadjuvant chemotherapy. But that proposal concerns resectable non-small-cell lung cancer, not the use of near-complete response as an endpoint in other cancer types. Section 5 discusses pathological complete response as an endpoint in breast cancer, without establishing the cited >90% threshold there. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This study from the NeoHCC consortium was designed to overcome this issue by pooling prospectively collected patient-level data from phase 1 and 2 clinical trials run in a consortium of tertiary referral centres.7,9,11,12”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Discussion
What the sources say
- Supportedcites [7] Marron, 2022, Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial, Lancet Gastroenterol Hepatol source
The Methods identify this paper as a single-arm, open-label phase 2 trial in patients with resectable hepatocellular carcinoma. In the multi-citation sentence, it serves to identify an individual trial; the pooling strategy describes the citing authors’ study, not this trial. (LLM, conf=0.86)
- Supportedcites [9] Ho, 2021, Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity, Nat Cancer source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [11] Pinato, 2021, PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma, BMC Cancer source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [12] Su, 2021, P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma, Ann Oncol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
52 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and to verify the 2 references still open.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 35
- Borderline: one of the tests for a substantial claim is unclear. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Radiological response was assessed with modified RECIST criteria in 81 (71%) patients”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Results
Reported 71 · recomputed 72.972973
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“For patients with portal vein tumoral thrombosis, Vp assessment was available in 13 (51%) patients”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Results
Reported 51 · recomputed 54.166667
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Abstract > Findings
“mostly ICI combinations (76 [69%])”
§ Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis > Results
“the remaining 76 (68%) patients were treated with combination therapy”
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Global burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
Self-citationNeoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919 · cited 2×
“%) patients had received at least one previous local therapy, most of whom had received one therapy (14 patients [13%]), including transarterial chemoembolisation (ten [9%]), surgery (seven [6%]), radiofrequency ablation (five [5%]), radioembolisation (three [3%]), and stereotactic body…”
Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000710 · Cited by 903 · cited 2×
“4 We used the non-parametric method for the ROC curve analysis because it does not assume any specific distribution of the test results and is robust across different types of data distributions.”
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01796-8 · Cited by 545
Cited by
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy
Seyhan, D., Allaire, M., Fu, Y., Conti, F., Wang, X. W., Gao, B., & Lafdil, F. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01308-4 · Cited by 162
Wang, Z., Fan, J., Zhou, S., Sun, Y., Liang, F., Ji, Y., Gu, F., Li, T., Peng, L., Peng, T., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01720-9 · Cited by 84
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma
Singal, A. G., Salem, R., Pinato, D. J., & Pillai, A. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.047 · Cited by 65
Self-citationLin, Y., Ou, D., Su, Y., Hsu, C., Hsiao, C., Ko, B., Chen, S., Wang, J., Wang, J.-H., Wu, Y., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.035 · Cited by 40
Self-citationEghbali, S. Z., & Heumann, T. R. (2025) · Cancers · doi:10.3390/cancers17020236 · Cited by 28
Metadata
- Authors
- D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., Pai, M., Goldin, R. D., Ward, S. C., Fiel, M. I., Shu, D. H., Su, Y.-Y., Cortellini, A., Baretti, M., Anders, R., Yarchoan, M., Hsu, C., Marron, T. U., & Pinato, D. J.
- Affiliations
- Imperial College London (GB)
- Mount Sinai Hospital (US)
- Barts Health NHS Trust (GB)
- National Health Service (GB)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- St Mary's Hospital (GB)
- Icahn School of Medicine at Mount Sinai (US)
- Johns Hopkins University (US)
- Kaohsiung Medical University (TW)
- Università Campus Bio-Medico (IT)
- National Taiwan University (TW)
- Corresponding author
- Pinato, David J
- ORCID
- Stefanini, Bernardo
- Blanter, Julia
- Adegbite, Benjamin
- Crowley, Fionnuala
- Yip, Vincent
- Slater, Sarah
- Fulgenzi, Claudia Angela Maria
- Celsa, Ciro
- Manfredi, Giulia Francesca
- Pai, Madhava
- Goldin, Robert D
- Ward, Stephen C
- Fiel, Maria Isabel
- Shu, Daniel H
- Su, Yung-Yeh
- Cortellini, Alessio
- Baretti, Marina
- Yarchoan, Mark
- Hsu, Chiun
- Marron, Thomas U
- Pinato, David J
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2024-11
- Volume
- 25
- Issue
- 11
- Pages
- 1465-1475
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC12040480
- OpenAlex
- W4403559173
- Cited by
- 90
- References
- 31
- Citations by year
- 2026: 42 · 2025: 46 · 2024: 2
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Oncology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- NHRI Institutional Repository (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- Airc Italian Foundation for Cancer Research (MFAG 25697)
- Cancer Research UK (RCCPDB\u2013Nov21/100008)
- Bristol-Myers Squibb (NCT03682276, NCT03916627)
- Foundation for Liver Research
- Wellcome Trust (PS3416)
- Associazione Italiana per la Ricerca sul Cancro
- European Association for the Study of the Liver
- Imperial Experimental Cancer Medicine Centre
- Cancer Treatment and Research Trust
- NIHR Imperial Biomedical Research Centre
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- hepatocellular carcinoma, pathological response, tumor regression, hepatectomy, relapse-free survival, pathological complete response, major pathological response, predictive biomarkers, immune-related adverse events, Barcelona Clinic Liver Cancer staging, immune checkpoint inhibitor combination, tumor-infiltrating lymphocytes
- MeSH terms
- Immune Checkpoint Inhibitors, Adult, Aged, Female, Hepatectomy, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(24)00457-1
- The paper
- D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., Pai, M., Goldin, R. D., Ward, S. C., Fiel, M. I., Shu, D. H., Su, Y.-Y., Cortellini, A., Baretti, M., Anders, R., . . . Pinato, D. J. (2024). Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(24)00457-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.